AcNK-Sup003 cell therapy for relapsed B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase trial tests a new immune cell treatment called AcNK-Sup003 for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to prior therapy. The goal is to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and expected to live more than 3 months.
- You have a type of B-cell lymphoma that is CD20-positive and has come back or not responded to at least two prior treatments, including a CD20-targeted drug and an anthracycline chemotherapy.
- You have at least one measurable tumor (lymph node >15 mm or other lesion >10 mm) seen on a PET scan.
- Your blood counts, kidney, liver, and lung function must meet certain minimum levels.
- You cannot have active central nervous system lymphoma, serious heart problems, active autoimmune disease, or uncontrolled infections.
- You must agree to use effective birth control for 6 months after the last treatment dose if you could become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new cellular therapy using immune cells (called CD20/CD19 cells) for patients with a certain type of lymphoma that has not been cured by standard treatments. The cells are designed to find and destroy your lymphoma cells, potentially helping you achieve remission.
This trial tests a new combination of specially grown immune cells (NK cells) plus two drugs that help them attack cancer. It's for people with a type of B-cell lymphoma that came back after at least two prior treatments or a stem cell transplant, and who have either failed or are not eligible for CAR-T cell therapy.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
This trial tests a new treatment using specially engineered immune cells (CAR-NK cells) that are designed to find and destroy leukemia cells. It may be an option for patients whose leukemia has come back or hasn't responded to other treatments.
This study tests whether adding your own natural killer (nk) cells (a type of immune cell) to your regular treatment helps fight non-hodgkin lymphoma that has come back or not responded. The goal is to see if this extra treatment is safe and works better at stopping the cancer.
This trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has come back after at least two prior treatments. It may help if you've already had rituximab or a similar antibody therapy.
Hear when a new B-cell Non-Hodgkin Lymphoma (B-NHL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.